Abstract:IntroductionA physiological feature of many tumor tissues and cells is the tendency to accumulate high concentrations of copper. While the precise role of copper in tumors is cryptic, copper, but not other trace metals, is required for angiogenesis. We have recently reported that organic copper-containing compounds, including 8-hydroxyquinoline-copper(II) and 5,7-dichloro-8-hydroxyquinoline-copper(II), comprise a novel class of proteasome inhibitors and tumor cell apoptosis inducers. In the current study, we investigate whether clioquinol (CQ), an analog of 8-hydroxyquinoline and an Alzheimer's disease drug, and pyrrolidine dithiocarbamate (PDTC), a known copper-binding compound and antioxidant, can interact with copper to form cancer-specific proteasome inhibitors and apoptosis inducers in human breast cancer cells. Tetrathiomolybdate (TM), a strong copper chelator currently being tested in clinical trials, is used as a comparison.MethodsBreast cell lines, normal, immortalized MCF-10A, premalignant MCF10AT1K.cl2, and malignant MCF10DCIS.com and MDA-MB-231, were treated with CQ or PDTC with or without prior interaction with copper, followed by measurement of proteasome inhibition and cell death. Inhibition of the proteasome was determined by levels of the proteasomal chymotrypsin-like activity and ubiquitinated proteins in protein extracts of the treated cells. Apoptotic cell death was measured by morphological changes, Hoechst staining, and poly(ADP-ribose) polymerase cleavage.ResultsWhen in complex with copper, both CQ and PDTC, but not TM, can inhibit the proteasome chymotrypsin-like activity, block proliferation, and induce apoptotic cell death preferentially in breast cancer cells, less in premalignant breast cells, but are non-toxic to normal/non-transformed breast cells at the concentrations tested. In contrast, CQ, PDTC, TM or copper alone had no effects on any of the cells. Breast premalignant or cancer cells that contain copper at concentrations similar to those found in patients, when treated with just CQ or PDTC alone, but not TM, undergo proteasome inhibition and apoptosis.ConclusionThe feature of breast cancer cells and tissues to accumulate copper can be used as a targeting method for anticancer therapy through treatment with novel compounds such as CQ and PDTC that become active proteasome inhibitors and breast cancer cell killers in the presence of copper.

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy

Cellular and Computational Studies of Proteasome Inhibition and Apoptosis Induction in Human Cancer Cells by Amino Acid Schiff Base–copper Complexes

Repurposing Old Drugs As New Inhibitors of the Ubiquitin-Proteasome Pathway for Cancer Treatment

Identification of 4-Arylidene Curcumin Analogues As Novel Proteasome Inhibitors for Potential Anticancer Agents Targeting 19S Regulatory Particle Associated Deubiquitinase

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Classification and Synthesis of Ubiquitinproteasome Inhibitor

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy

Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells

l -Ornithine Schiff base–copper and –cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

Synthesis and Mechanistic Studies of Quinolin-Chlorobenzothioate Derivatives with Proteasome Inhibitory Activity in Pancreatic Cancer Cell Lines.

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

Proteasome Inhibitor Interacts Synergistically with Autophagy Inhibitor to Suppress Proliferation and Induce Apoptosis in Hepatocellular Carcinoma

Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.

Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells

Abstract 2795: Screening and characterization of drugs that inhibit the ubiquitin-proteasome system

Inhibition of Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 2 Perturbs 26S Proteasome-Addicted Neoplastic Progression

Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment

Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer

Proteasome Inhibition: A New Therapeutic Strategy to Cancer Treatment